Dynavax Technologies | DVAX - Cost Of Sales

Stock Price
15.50
Daily Change
0.01 0.06%
Monthly
0.58%
Yearly
17.87%
Q1 Forecast
15.01

Dynavax Technologies reported $14.4M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Adma Biologics USD 58.64M 3.88M Sep/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 2.8B 328M Sep/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Dynavax Technologies USD 14.4M 368K Sep/2025
Gilead Sciences USD 1.57B 68M Sep/2025
Glaxosmithkline GBP 3.01B 853.01M Sep/2025
Merck USD 3.32B 531M Dec/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Novartis USD 3.54B 217M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
TG Therapeutics USD 28.09M 9.15M Sep/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025